These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27532938)

  • 1. Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.
    Malm M; Frejd FY; Ståhl S; Löfblom J
    MAbs; 2016 Oct; 8(7):1195-1209. PubMed ID: 27532938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.
    Malm M; Bass T; Gudmundsdotter L; Lord M; Frejd FY; Ståhl S; Löfblom J
    Biotechnol J; 2014 Sep; 9(9):1215-22. PubMed ID: 24678002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER3/ErbB3, an emerging cancer therapeutic target.
    Zhang N; Chang Y; Rios A; An Z
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.
    Kol A; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Lamberts LE; Bensch F; de Vries EG; Schröder CP
    Pharmacol Ther; 2014 Jul; 143(1):1-11. PubMed ID: 24513440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer.
    Majumder A
    Cells; 2023 Oct; 12(21):. PubMed ID: 37947595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER3 signaling and targeted therapy in cancer.
    Mishra R; Patel H; Alanazi S; Yuan L; Garrett JT
    Oncol Rev; 2018 Jan; 12(1):355. PubMed ID: 30057690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.
    Jacob W; James I; Hasmann M; Weisser M
    Cancer Treat Rev; 2018 Jul; 68():111-123. PubMed ID: 29944978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.
    Robinson MK; Hodge KM; Horak E; Sundberg AL; Russeva M; Shaller CC; von Mehren M; Shchaveleva I; Simmons HH; Marks JD; Adams GP
    Br J Cancer; 2008 Nov; 99(9):1415-25. PubMed ID: 18841159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ; Scollard DA; Reilly RM
    J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2.
    Ekerljung L; Wållberg H; Sohrabian A; Andersson K; Friedman M; Frejd FY; Ståhl S; Gedda L
    Bioconjug Chem; 2012 Sep; 23(9):1802-11. PubMed ID: 22882002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies.
    Harms BD; Kearns JD; Iadevaia S; Lugovskoy AA
    Methods; 2014 Jan; 65(1):95-104. PubMed ID: 23872324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies.
    Hassani D; Jeddi-Tehrani M; Yousefi P; Mansouri-Fard S; Mobini M; Ahmadi-Zare H; Golsaz-Shirazi F; Amiri MM; Shokri F
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):347-361. PubMed ID: 35079876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of HER3 targeting in cancer using monoclonal antibodies.
    Gaborit N; Abdul-Hai A; Mancini M; Lindzen M; Lavi S; Leitner O; Mounier L; Chentouf M; Dunoyer S; Ghosh M; Larbouret C; Chardès T; Bazin H; Pèlegrin A; Sela M; Yarden Y
    Proc Natl Acad Sci U S A; 2015 Jan; 112(3):839-44. PubMed ID: 25564668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
    Schaefer G; Haber L; Crocker LM; Shia S; Shao L; Dowbenko D; Totpal K; Wong A; Lee CV; Stawicki S; Clark R; Fields C; Lewis Phillips GD; Prell RA; Danilenko DM; Franke Y; Stephan JP; Hwang J; Wu Y; Bostrom J; Sliwkowski MX; Fuh G; Eigenbrot C
    Cancer Cell; 2011 Oct; 20(4):472-86. PubMed ID: 22014573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
    Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.
    Schoeberl B; Pace EA; Fitzgerald JB; Harms BD; Xu L; Nie L; Linggi B; Kalra A; Paragas V; Bukhalid R; Grantcharova V; Kohli N; West KA; Leszczyniecka M; Feldhaus MJ; Kudla AJ; Nielsen UB
    Sci Signal; 2009 Jun; 2(77):ra31. PubMed ID: 19567914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.
    Gaborit N; Lindzen M; Yarden Y
    Hum Vaccin Immunother; 2016 Mar; 12(3):576-92. PubMed ID: 26529100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.